nodes	percent_of_prediction	percent_of_DWPC	metapath
Ciclesonide—CYP3A4—bone cancer	0.928	1	CbGaD
Ciclesonide—Fluocinonide—SMO—bone cancer	0.00557	0.522	CrCbGaD
Ciclesonide—Obstructive airways disorder—Methotrexate—bone cancer	0.00236	0.0457	CcSEcCtD
Ciclesonide—Musculoskeletal chest pain—Epirubicin—bone cancer	0.00129	0.025	CcSEcCtD
Ciclesonide—Impaired healing—Methotrexate—bone cancer	0.00124	0.024	CcSEcCtD
Ciclesonide—Rhinorrhoea—Cisplatin—bone cancer	0.00121	0.0233	CcSEcCtD
Ciclesonide—Laboratory test abnormal—Epirubicin—bone cancer	0.0012	0.0232	CcSEcCtD
Ciclesonide—Musculoskeletal chest pain—Doxorubicin—bone cancer	0.0012	0.0232	CcSEcCtD
Ciclesonide—CES1—Irinotecan Pathway—CYP3A4—bone cancer	0.00119	0.121	CbGpPWpGaD
Ciclesonide—Infection—Carboplatin—bone cancer	0.00118	0.0228	CcSEcCtD
Ciclesonide—Laboratory test abnormal—Doxorubicin—bone cancer	0.00111	0.0215	CcSEcCtD
Ciclesonide—Ulcer—Cisplatin—bone cancer	0.00103	0.02	CcSEcCtD
Ciclesonide—Osteoporosis—Methotrexate—bone cancer	0.000957	0.0185	CcSEcCtD
Ciclesonide—Wheezing—Cisplatin—bone cancer	0.000949	0.0184	CcSEcCtD
Ciclesonide—Multiple fractures—Methotrexate—bone cancer	0.000923	0.0178	CcSEcCtD
Ciclesonide—Fracture—Methotrexate—bone cancer	0.000923	0.0178	CcSEcCtD
Ciclesonide—NR3C1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.000817	0.0835	CbGpPWpGaD
Ciclesonide—Oral candidiasis—Epirubicin—bone cancer	0.00079	0.0153	CcSEcCtD
Ciclesonide—Hydrocortamate—CYP3A4—bone cancer	0.000789	0.0739	CrCbGaD
Ciclesonide—Nasal congestion—Cisplatin—bone cancer	0.000779	0.0151	CcSEcCtD
Ciclesonide—Budesonide—CYP3A4—bone cancer	0.000733	0.0687	CrCbGaD
Ciclesonide—Oral candidiasis—Doxorubicin—bone cancer	0.000731	0.0141	CcSEcCtD
Ciclesonide—CES1—Fluoropyrimidine Activity—DHFR—bone cancer	0.000707	0.0722	CbGpPWpGaD
Ciclesonide—Face oedema—Cisplatin—bone cancer	0.000685	0.0132	CcSEcCtD
Ciclesonide—Nasopharyngitis—Cisplatin—bone cancer	0.000634	0.0123	CcSEcCtD
Ciclesonide—Alclometasone—CYP3A4—bone cancer	0.000632	0.0592	CrCbGaD
Ciclesonide—Flunisolide—CYP3A4—bone cancer	0.000615	0.0576	CrCbGaD
Ciclesonide—Dysphonia—Epirubicin—bone cancer	0.00061	0.0118	CcSEcCtD
Ciclesonide—Paramethasone—CYP3A4—bone cancer	0.000608	0.0569	CrCbGaD
Ciclesonide—Methylprednisolone—CYP3A4—bone cancer	0.000573	0.0537	CrCbGaD
Ciclesonide—Ulcer—Methotrexate—bone cancer	0.000567	0.011	CcSEcCtD
Ciclesonide—Dysphonia—Doxorubicin—bone cancer	0.000564	0.0109	CcSEcCtD
Ciclesonide—Conjunctivitis—Cisplatin—bone cancer	0.000531	0.0103	CcSEcCtD
Ciclesonide—Ulcer—Epirubicin—bone cancer	0.000531	0.0103	CcSEcCtD
Ciclesonide—Ulcer—Doxorubicin—bone cancer	0.000491	0.0095	CcSEcCtD
Ciclesonide—Candida infection—Epirubicin—bone cancer	0.000479	0.00927	CcSEcCtD
Ciclesonide—Diabetes mellitus—Methotrexate—bone cancer	0.000447	0.00866	CcSEcCtD
Ciclesonide—Candida infection—Doxorubicin—bone cancer	0.000443	0.00858	CcSEcCtD
Ciclesonide—Immune system disorder—Cisplatin—bone cancer	0.000443	0.00857	CcSEcCtD
Ciclesonide—Mediastinal disorder—Cisplatin—bone cancer	0.000442	0.00856	CcSEcCtD
Ciclesonide—Prednisone—CYP3A4—bone cancer	0.000438	0.0411	CrCbGaD
Ciclesonide—Diabetes mellitus—Epirubicin—bone cancer	0.000419	0.0081	CcSEcCtD
Ciclesonide—Prednisolone—CYP3A4—bone cancer	0.000404	0.0379	CrCbGaD
Ciclesonide—Diabetes mellitus—Doxorubicin—bone cancer	0.000387	0.0075	CcSEcCtD
Ciclesonide—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.000387	0.0395	CbGpPWpGaD
Ciclesonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—ATF1—bone cancer	0.000381	0.0389	CbGpPWpGaD
Ciclesonide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000376	0.0383	CbGpPWpGaD
Ciclesonide—CES1—E2F transcription factor network—DHFR—bone cancer	0.000375	0.0383	CbGpPWpGaD
Ciclesonide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000374	0.0382	CbGpPWpGaD
Ciclesonide—NR3C1—Nuclear Receptors—NR1I2—bone cancer	0.000365	0.0373	CbGpPWpGaD
Ciclesonide—Pain in extremity—Epirubicin—bone cancer	0.000364	0.00705	CcSEcCtD
Ciclesonide—Face oedema—Epirubicin—bone cancer	0.000352	0.0068	CcSEcCtD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—FEV—bone cancer	0.000348	0.0356	CbGpPWpGaD
Ciclesonide—Infection—Cisplatin—bone cancer	0.000346	0.0067	CcSEcCtD
Ciclesonide—Pain in extremity—Doxorubicin—bone cancer	0.000337	0.00652	CcSEcCtD
Ciclesonide—Nasopharyngitis—Epirubicin—bone cancer	0.000326	0.0063	CcSEcCtD
Ciclesonide—Face oedema—Doxorubicin—bone cancer	0.000325	0.00629	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000321	0.00621	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000318	0.00614	CcSEcCtD
Ciclesonide—Influenza—Epirubicin—bone cancer	0.000315	0.00609	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Methotrexate—bone cancer	0.000313	0.00605	CcSEcCtD
Ciclesonide—Dyspnoea—Cisplatin—bone cancer	0.000311	0.00601	CcSEcCtD
Ciclesonide—Hydrocortisone—CYP3A4—bone cancer	0.000309	0.029	CrCbGaD
Ciclesonide—Bronchitis—Epirubicin—bone cancer	0.000303	0.00586	CcSEcCtD
Ciclesonide—Pneumonia—Methotrexate—bone cancer	0.000302	0.00584	CcSEcCtD
Ciclesonide—Nasopharyngitis—Doxorubicin—bone cancer	0.000301	0.00583	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000301	0.00582	CcSEcCtD
Ciclesonide—Infestation NOS—Methotrexate—bone cancer	0.0003	0.0058	CcSEcCtD
Ciclesonide—Infestation—Methotrexate—bone cancer	0.0003	0.0058	CcSEcCtD
Ciclesonide—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000297	0.00575	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Epirubicin—bone cancer	0.000293	0.00566	CcSEcCtD
Ciclesonide—Conjunctivitis—Methotrexate—bone cancer	0.000292	0.00564	CcSEcCtD
Ciclesonide—Influenza—Doxorubicin—bone cancer	0.000291	0.00564	CcSEcCtD
Ciclesonide—NR3C1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000289	0.0295	CbGpPWpGaD
Ciclesonide—Weight increased—Epirubicin—bone cancer	0.000287	0.00554	CcSEcCtD
Ciclesonide—Epistaxis—Methotrexate—bone cancer	0.000283	0.00547	CcSEcCtD
Ciclesonide—Pneumonia—Epirubicin—bone cancer	0.000282	0.00546	CcSEcCtD
Ciclesonide—Infestation NOS—Epirubicin—bone cancer	0.000281	0.00543	CcSEcCtD
Ciclesonide—Infestation—Epirubicin—bone cancer	0.000281	0.00543	CcSEcCtD
Ciclesonide—Bronchitis—Doxorubicin—bone cancer	0.00028	0.00542	CcSEcCtD
Ciclesonide—Conjunctivitis—Epirubicin—bone cancer	0.000273	0.00528	CcSEcCtD
Ciclesonide—Urinary tract infection—Epirubicin—bone cancer	0.000273	0.00528	CcSEcCtD
Ciclesonide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000271	0.00524	CcSEcCtD
Ciclesonide—Haemoglobin—Methotrexate—bone cancer	0.000271	0.00524	CcSEcCtD
Ciclesonide—Haemorrhage—Methotrexate—bone cancer	0.000269	0.00521	CcSEcCtD
Ciclesonide—Pharyngitis—Methotrexate—bone cancer	0.000267	0.00517	CcSEcCtD
Ciclesonide—Weight increased—Doxorubicin—bone cancer	0.000265	0.00513	CcSEcCtD
Ciclesonide—Epistaxis—Epirubicin—bone cancer	0.000265	0.00512	CcSEcCtD
Ciclesonide—Sinusitis—Epirubicin—bone cancer	0.000263	0.00509	CcSEcCtD
Ciclesonide—Pneumonia—Doxorubicin—bone cancer	0.000261	0.00505	CcSEcCtD
Ciclesonide—Infestation NOS—Doxorubicin—bone cancer	0.00026	0.00502	CcSEcCtD
Ciclesonide—Infestation—Doxorubicin—bone cancer	0.00026	0.00502	CcSEcCtD
Ciclesonide—Haemoglobin—Epirubicin—bone cancer	0.000253	0.0049	CcSEcCtD
Ciclesonide—Rhinitis—Epirubicin—bone cancer	0.000253	0.00489	CcSEcCtD
Ciclesonide—Conjunctivitis—Doxorubicin—bone cancer	0.000252	0.00488	CcSEcCtD
Ciclesonide—Urinary tract infection—Doxorubicin—bone cancer	0.000252	0.00488	CcSEcCtD
Ciclesonide—Haemorrhage—Epirubicin—bone cancer	0.000252	0.00487	CcSEcCtD
Ciclesonide—Asthenia—Cisplatin—bone cancer	0.00025	0.00484	CcSEcCtD
Ciclesonide—Pharyngitis—Epirubicin—bone cancer	0.00025	0.00484	CcSEcCtD
Ciclesonide—Epistaxis—Doxorubicin—bone cancer	0.000245	0.00474	CcSEcCtD
Ciclesonide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000244	0.025	CbGpPWpGaD
Ciclesonide—Sinusitis—Doxorubicin—bone cancer	0.000244	0.00471	CcSEcCtD
Ciclesonide—Immune system disorder—Methotrexate—bone cancer	0.000243	0.00471	CcSEcCtD
Ciclesonide—Mediastinal disorder—Methotrexate—bone cancer	0.000243	0.00469	CcSEcCtD
Ciclesonide—Haemoglobin—Doxorubicin—bone cancer	0.000234	0.00453	CcSEcCtD
Ciclesonide—Rhinitis—Doxorubicin—bone cancer	0.000234	0.00452	CcSEcCtD
Ciclesonide—Haemorrhage—Doxorubicin—bone cancer	0.000233	0.00451	CcSEcCtD
Ciclesonide—Pharyngitis—Doxorubicin—bone cancer	0.000231	0.00448	CcSEcCtD
Ciclesonide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00023	0.0235	CbGpPWpGaD
Ciclesonide—Dysgeusia—Methotrexate—bone cancer	0.00023	0.00444	CcSEcCtD
Ciclesonide—Immune system disorder—Epirubicin—bone cancer	0.000228	0.0044	CcSEcCtD
Ciclesonide—Mediastinal disorder—Epirubicin—bone cancer	0.000227	0.00439	CcSEcCtD
Ciclesonide—Back pain—Methotrexate—bone cancer	0.000227	0.00439	CcSEcCtD
Ciclesonide—Rash—Cisplatin—bone cancer	0.00022	0.00425	CcSEcCtD
Ciclesonide—Dermatitis—Cisplatin—bone cancer	0.00022	0.00425	CcSEcCtD
Ciclesonide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000216	0.022	CbGpPWpGaD
Ciclesonide—Dysgeusia—Epirubicin—bone cancer	0.000215	0.00416	CcSEcCtD
Ciclesonide—Back pain—Epirubicin—bone cancer	0.000212	0.0041	CcSEcCtD
Ciclesonide—Immune system disorder—Doxorubicin—bone cancer	0.000211	0.00407	CcSEcCtD
Ciclesonide—Mediastinal disorder—Doxorubicin—bone cancer	0.00021	0.00407	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—PLAU—bone cancer	0.000208	0.0213	CbGpPWpGaD
Ciclesonide—Nausea—Cisplatin—bone cancer	0.000207	0.00401	CcSEcCtD
Ciclesonide—Cough—Methotrexate—bone cancer	0.000205	0.00396	CcSEcCtD
Ciclesonide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—bone cancer	0.000204	0.0208	CbGpPWpGaD
Ciclesonide—Chest pain—Methotrexate—bone cancer	0.0002	0.00386	CcSEcCtD
Ciclesonide—Arthralgia—Methotrexate—bone cancer	0.0002	0.00386	CcSEcCtD
Ciclesonide—Dysgeusia—Doxorubicin—bone cancer	0.000199	0.00385	CcSEcCtD
Ciclesonide—Back pain—Doxorubicin—bone cancer	0.000196	0.0038	CcSEcCtD
Ciclesonide—Palpitations—Epirubicin—bone cancer	0.000194	0.00375	CcSEcCtD
Ciclesonide—Cough—Epirubicin—bone cancer	0.000191	0.0037	CcSEcCtD
Ciclesonide—Infection—Methotrexate—bone cancer	0.00019	0.00368	CcSEcCtD
Ciclesonide—Hypertension—Epirubicin—bone cancer	0.000189	0.00366	CcSEcCtD
Ciclesonide—Chest pain—Epirubicin—bone cancer	0.000187	0.00361	CcSEcCtD
Ciclesonide—Arthralgia—Epirubicin—bone cancer	0.000187	0.00361	CcSEcCtD
Ciclesonide—Dry mouth—Epirubicin—bone cancer	0.000183	0.00353	CcSEcCtD
Ciclesonide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00018	0.0184	CbGpPWpGaD
Ciclesonide—Palpitations—Doxorubicin—bone cancer	0.000179	0.00347	CcSEcCtD
Ciclesonide—Infection—Epirubicin—bone cancer	0.000178	0.00344	CcSEcCtD
Ciclesonide—Cough—Doxorubicin—bone cancer	0.000177	0.00343	CcSEcCtD
Ciclesonide—Hypertension—Doxorubicin—bone cancer	0.000175	0.00339	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000174	0.00337	CcSEcCtD
Ciclesonide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000174	0.0177	CbGpPWpGaD
Ciclesonide—Arthralgia—Doxorubicin—bone cancer	0.000173	0.00334	CcSEcCtD
Ciclesonide—Chest pain—Doxorubicin—bone cancer	0.000173	0.00334	CcSEcCtD
Ciclesonide—CES1—E2F transcription factor network—RB1—bone cancer	0.000171	0.0175	CbGpPWpGaD
Ciclesonide—Dyspnoea—Methotrexate—bone cancer	0.000171	0.0033	CcSEcCtD
Ciclesonide—Dry mouth—Doxorubicin—bone cancer	0.000169	0.00327	CcSEcCtD
Ciclesonide—Dyspepsia—Methotrexate—bone cancer	0.000168	0.00326	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000165	0.0032	CcSEcCtD
Ciclesonide—Fatigue—Methotrexate—bone cancer	0.000165	0.00319	CcSEcCtD
Ciclesonide—Infection—Doxorubicin—bone cancer	0.000165	0.00318	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000163	0.00316	CcSEcCtD
Ciclesonide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000161	0.0164	CbGpPWpGaD
Ciclesonide—Dyspnoea—Epirubicin—bone cancer	0.00016	0.00309	CcSEcCtD
Ciclesonide—CES1—Fluoropyrimidine Activity—TP53—bone cancer	0.000158	0.0161	CbGpPWpGaD
Ciclesonide—Dyspepsia—Epirubicin—bone cancer	0.000158	0.00305	CcSEcCtD
Ciclesonide—CES1—NRF2 pathway—TGFBR2—bone cancer	0.000156	0.0159	CbGpPWpGaD
Ciclesonide—CES1—NRF2 pathway—GSTP1—bone cancer	0.000156	0.0159	CbGpPWpGaD
Ciclesonide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000155	0.00299	CcSEcCtD
Ciclesonide—Fatigue—Epirubicin—bone cancer	0.000154	0.00299	CcSEcCtD
Ciclesonide—Urticaria—Methotrexate—bone cancer	0.000152	0.00294	CcSEcCtD
Ciclesonide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000151	0.00292	CcSEcCtD
Ciclesonide—Dyspnoea—Doxorubicin—bone cancer	0.000148	0.00286	CcSEcCtD
Ciclesonide—NR3C1—Generic Transcription Pathway—ZNF77—bone cancer	0.000147	0.015	CbGpPWpGaD
Ciclesonide—NR3C1—Endoderm Differentiation—EZH2—bone cancer	0.000147	0.015	CbGpPWpGaD
Ciclesonide—Dyspepsia—Doxorubicin—bone cancer	0.000146	0.00282	CcSEcCtD
Ciclesonide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000143	0.00277	CcSEcCtD
Ciclesonide—Fatigue—Doxorubicin—bone cancer	0.000143	0.00276	CcSEcCtD
Ciclesonide—Urticaria—Epirubicin—bone cancer	0.000142	0.00275	CcSEcCtD
Ciclesonide—Asthenia—Methotrexate—bone cancer	0.000137	0.00266	CcSEcCtD
Ciclesonide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000132	0.0135	CbGpPWpGaD
Ciclesonide—Urticaria—Doxorubicin—bone cancer	0.000132	0.00255	CcSEcCtD
Ciclesonide—Asthenia—Epirubicin—bone cancer	0.000128	0.00248	CcSEcCtD
Ciclesonide—Dizziness—Methotrexate—bone cancer	0.000127	0.00245	CcSEcCtD
Ciclesonide—Rash—Methotrexate—bone cancer	0.000121	0.00233	CcSEcCtD
Ciclesonide—Dermatitis—Methotrexate—bone cancer	0.000121	0.00233	CcSEcCtD
Ciclesonide—Headache—Methotrexate—bone cancer	0.00012	0.00232	CcSEcCtD
Ciclesonide—Asthenia—Doxorubicin—bone cancer	0.000119	0.0023	CcSEcCtD
Ciclesonide—Dizziness—Epirubicin—bone cancer	0.000118	0.00229	CcSEcCtD
Ciclesonide—Nausea—Methotrexate—bone cancer	0.000114	0.0022	CcSEcCtD
Ciclesonide—Rash—Epirubicin—bone cancer	0.000113	0.00218	CcSEcCtD
Ciclesonide—Dermatitis—Epirubicin—bone cancer	0.000113	0.00218	CcSEcCtD
Ciclesonide—Headache—Epirubicin—bone cancer	0.000112	0.00217	CcSEcCtD
Ciclesonide—Dizziness—Doxorubicin—bone cancer	0.00011	0.00212	CcSEcCtD
Ciclesonide—Nausea—Epirubicin—bone cancer	0.000106	0.00206	CcSEcCtD
Ciclesonide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000105	0.0107	CbGpPWpGaD
Ciclesonide—Rash—Doxorubicin—bone cancer	0.000104	0.00202	CcSEcCtD
Ciclesonide—Dermatitis—Doxorubicin—bone cancer	0.000104	0.00202	CcSEcCtD
Ciclesonide—Headache—Doxorubicin—bone cancer	0.000104	0.00201	CcSEcCtD
Ciclesonide—Nausea—Doxorubicin—bone cancer	9.84e-05	0.0019	CcSEcCtD
Ciclesonide—NR3C1—AP-1 transcription factor network—PLAU—bone cancer	8.58e-05	0.00876	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of Androgen receptor activity—MDM2—bone cancer	7.51e-05	0.00767	CbGpPWpGaD
Ciclesonide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	7.49e-05	0.00765	CbGpPWpGaD
Ciclesonide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	7.39e-05	0.00755	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	7.22e-05	0.00737	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—ZNF77—bone cancer	7.09e-05	0.00724	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of Androgen receptor activity—JUN—bone cancer	6.53e-05	0.00667	CbGpPWpGaD
Ciclesonide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	6.07e-05	0.0062	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—bone cancer	5.3e-05	0.00541	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—JUN—bone cancer	5.23e-05	0.00534	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—MMP9—bone cancer	5.09e-05	0.00519	CbGpPWpGaD
Ciclesonide—NR3C1—Generic Transcription Pathway—NR1I2—bone cancer	4.98e-05	0.00509	CbGpPWpGaD
Ciclesonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	4.65e-05	0.00475	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—JUN—bone cancer	4.61e-05	0.0047	CbGpPWpGaD
Ciclesonide—NR3C1—Adipogenesis—RB1—bone cancer	4.3e-05	0.00439	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—FUS—bone cancer	3.46e-05	0.00353	CbGpPWpGaD
Ciclesonide—NR3C1—AP-1 transcription factor network—TP53—bone cancer	3.45e-05	0.00352	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	3.23e-05	0.00329	CbGpPWpGaD
Ciclesonide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	3.18e-05	0.00325	CbGpPWpGaD
Ciclesonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—bone cancer	3.04e-05	0.0031	CbGpPWpGaD
Ciclesonide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.78e-05	0.00284	CbGpPWpGaD
Ciclesonide—CYP2D6—Biological oxidations—GSTP1—bone cancer	2.76e-05	0.00282	CbGpPWpGaD
Ciclesonide—NR3C1—SIDS Susceptibility Pathways—JUN—bone cancer	2.75e-05	0.00281	CbGpPWpGaD
Ciclesonide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	2.72e-05	0.00278	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—NR1I2—bone cancer	2.4e-05	0.00245	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NDUFA12—bone cancer	1.93e-05	0.00197	CbGpPWpGaD
Ciclesonide—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.8e-05	0.00184	CbGpPWpGaD
Ciclesonide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.78e-05	0.00182	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—EIF2S1—bone cancer	1.77e-05	0.00181	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—NT5C3A—bone cancer	1.6e-05	0.00164	CbGpPWpGaD
Ciclesonide—NR3C1—Gene Expression—EZH2—bone cancer	1.54e-05	0.00157	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NDUFA12—bone cancer	1.26e-05	0.00129	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—NT5C3A—bone cancer	1.05e-05	0.00107	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—ENO2—bone cancer	7.02e-06	0.000717	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—DHFR—bone cancer	6.51e-06	0.000665	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GNA11—bone cancer	6.09e-06	0.000621	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—CYP3A4—bone cancer	5.52e-06	0.000563	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—GSTP1—bone cancer	4.72e-06	0.000482	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—ENO2—bone cancer	4.59e-06	0.000469	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—DHFR—bone cancer	4.26e-06	0.000435	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GNA11—bone cancer	3.98e-06	0.000406	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—GSTP1—bone cancer	3.09e-06	0.000315	CbGpPWpGaD
Ciclesonide—CYP2D6—Metabolism—PTGS2—bone cancer	2.45e-06	0.00025	CbGpPWpGaD
Ciclesonide—CYP3A4—Metabolism—PTGS2—bone cancer	1.6e-06	0.000163	CbGpPWpGaD
